Indulis Kumsars

Indulis Kumsars

Auto-generated profile, based on publicly available information

Indulis Kumsars

Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in The Lancet
Verified
Journal Article
Open access
TMTimo Mäkikallio
Timo Mäkikallio
NHNiels R Holm
Niels R Holm
MLMitchell Lindsay
Mitchell Lindsay
MSMark S Spence
Mark S Spence
AEAndrejs Erglis
Andrejs Erglis
ECEvald Høj Christiansen
Evald Høj Christiansen
Coronary artery bypass grafting (CABG) is the standard treatment for revascularisation in patients with left main coronary artery disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. We aimed to compare PCI and CABG for treatment of left main coronary artery disease. In this prospective, randomised, open-label, non-inferiority trial, patients with left main coronary artery disease were enrolled in 36 centres in northern Europe and randomised 1:1 to treatment with PCI or CABG. Eligible patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction. Exclusion criteria were ST-elevation myocardial infarction within 24 h, being considered too high risk for CABG or PCI, or expected survival of less than 1 year. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCE), a composite of all-cause mortality, non-procedural myocardial infarction, any repeat coronary revascularisation, and stroke. Non-inferiority of PCI to CABG required the lower end of the 95% CI not to exceed a hazard ratio (HR) of 1·35 after up to 5 years of follow-up. The intention-to-treat principle was used in the analysis if not specified otherwise. This trial is registered with ClinicalTrials.gov identifier, number NCT01496651. Between Dec 9, 2008, and Jan 21, 2015, 1201 patients were randomly assigned, 598 to PCI and 603 to CABG, and 592 in each group entered analysis by intention to treat. Kaplan-Meier 5 year estimates of MACCE were 29% for PCI (121 events) and 19% for CABG (81 events), HR 1·48 (95% CI 1·11-1·96), exceeding the limit for non-inferiority, and CABG was significantly better than PCI (p=0·0066). As-treated estimates were 28% versus 19% (1·55, 1·18-2·04, p=0·0015). Comparing PCI with CABG, 5 year estimates were 12% versus 9% (1·07, 0·67-1·72, p=0·77) for all-cause mortality, 7% versus 2% (2·88, 1·40-5·90, p=0·0040) for non-procedural myocardial infarction, 16% versus 10% (1·50, 1·04-2·17, p=0·032) for any revascularisation, and 5% versus 2% (2·25, 0·93-5·48, p=0·073) for stroke. The findings of this study suggest that CABG might be better than PCI for treatment of left main stem coronary artery disease. Biosensors, Aarhus University Hospital, and participating sites.

31 October 2006 in Circulation
Verified
Journal Article
Closed access
PDF file
TSTerje K. Steigen
Terje K. Steigen
MMMichael Maeng
Michael Maeng
RWRune Wiseth
Rune Wiseth
AEAndrejs Erglis
Andrejs Erglis
IKIndulis Kumsars
Indulis Kumsars
LTLeif Thuesen
Leif Thuesen
Background— The optimal stenting strategy in coronary artery bifurcation lesions is unknown. In the present study, a strategy of stenting both the main vessel and the side branch (MV+SB) was compared with a strategy of stenting the main vessel only, with optional stenting of the side branch (MV), with sirolimus-eluting stents. Methods and Results— A total of 413 patients with a bifurcation lesion were randomized. The primary end point was a major adverse cardiac event: cardiac death, myocardial infarction, target-vessel revascularization, or stent thrombosis after 6 months. At 6 months, there were no significant differences in rates of major adverse cardiac events between the groups (MV+SB 3.4%, MV 2.9%; P =NS). In the MV+SB group, there were significantly longer procedure and fluoroscopy times, higher contrast volumes, and higher rates of procedure-related increases in biomarkers of myocardial injury. A total of 307 patients had a quantitative coronary assessment at the index procedure and after 8 months. The combined angiographic end point of diameter stenosis >50% of main vessel and occlusion of the side branch after 8 months was found in 5.3% in the MV group and 5.1% in the MV+SB group ( P =NS). Conclusions— Independent of stenting strategy, excellent clinical and angiographic results were obtained with percutaneous treatment of de novo coronary artery bifurcation lesions with sirolimus-eluting stents. The simple stenting strategy used in the MV group was associated with reduced procedure and fluoroscopy times and lower rates of procedure-related biomarker elevation. Therefore, this strategy can be recommended as the routine bifurcation stenting technique.

1 January 2020 in The Lancet
Verified
Journal Article
Closed access
NHNiels R Holm
Niels R Holm
TMTimo Mäkikallio
Timo Mäkikallio
MLM Mitchell Lindsay
M Mitchell Lindsay
MSMark S Spence
Mark S Spence
AEAndrejs Erglis
Andrejs Erglis
JHJuha Hartikainen
Juha Hartikainen

1 January 2011 in Circulation
Verified
Journal Article
Closed access
MNMatti Niemelä
Matti Niemelä
KKKari Kervinen
Kari Kervinen
AEAndrejs Erglis
Andrejs Erglis
NHNiels R Holm
Niels R Holm
MMMichael Maeng
Michael Maeng
NGNordic-Baltic PCI Study Group
Nordic-Baltic PCI Study Group
Background—: It is unknown whether the preferred 1-stent bifurcation stenting approach with stenting of the main vessel (MV) and optional side branch stenting using drug-eluting stents should be finalized by a kissing balloon dilatation (FKBD). Therefore, we compared strategies of MV stenting with and without FKBD. Methods and Results—: We randomized 477 patients with a bifurcation lesion to FKBD (n=238) or no FKBD (n=239) after MV stenting. The primary end point was major adverse cardiac events: cardiac death, non–procedure-related index lesion myocardial infarction, target lesion revascularization, or stent thrombosis within 6 months. The 6-month major adverse cardiac event rates were 2.1% and 2.5% ( P =1.00) in the FKBD and no-FKBD groups, respectively. Procedure and fluoroscopy times were longer and more contrast media was needed in the FKBD group than in the no-FKBD group. Three hundred twenty-six patients had a quantitative coronary assessment. At 8 months, the rate of binary (re)stenosis in the entire bifurcation lesion (MV and side branch) was 11.0% versus 17.3% ( P =0.11), in the MV was 3.1% versus 2.5% ( P =0.68), and in the side branch was 7.9% versus 15.4% ( P =0.039) in the FKBD versus no-FKBD groups, respectively. In patients with true bifurcation lesions, the side branch restenosis rate was 7.6% versus 20.0% ( P =0.024) in the FKBD and no-FKBD groups, respectively. Conclusions—: MV stenting strategies with and without FKBD were associated with similar clinical outcomes. FKBD reduced angiographic side branch (re)stenosis, especially in patients with true bifurcation lesions. The simple no-FKBD procedures resulted in reduced use of contrast media and shorter procedure and fluoroscopy times. Long-term data on stent thrombosis are needed. Clinical Trial Registration—: URL: http://clinicaltrials.gov . Unique identifier: NCT00914199.

1 July 2013 in JACC
Verified
Journal Article
Closed access
MMMichael Maeng
Michael Maeng
NHNiels R. Holm
Niels R. Holm
AEAndrejs Erglis
Andrejs Erglis
IKIndulis Kumsars
Indulis Kumsars
MNMatti Niemelä
Matti Niemelä
LTLeif Thuesen
Leif Thuesen

1 February 2009 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
AEAndrejs Erglis
Andrejs Erglis
IKIndulis Kumsars
Indulis Kumsars
MNMatti Niemelä
Matti Niemelä
KKKari Kervinen
Kari Kervinen
MMMichael Maeng
Michael Maeng
LTLeif Thuesen
Leif Thuesen
Background— In a number of coronary bifurcation lesions, both the main vessel and the side branch need stent coverage. Using sirolimus eluting stents, we compared 2 dedicated bifurcation stent techniques, the crush and the culotte techniques in a randomized trial with separate clinical and angiographic end-points. Methods and Results— A total of 424 patients with a bifurcation lesion were randomized to crush (n=209) and culotte (n=215) stenting. The primary end point was major adverse cardiac events; cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis after 6 months. At 6 months there were no significant differences in major adverse cardiac event rates between the groups; crush 4.3%, culotte 3.7% ( P =0.87). Procedure and fluoroscopy times and contrast volumes were similar in the 2 groups. The rates of procedure-related increase in biomarkers of myocardial injury were 15.5% in crush versus 8.8% in culotte group ( P =0.08). A total of 324 patients had a quantitative coronary assessment at the index procedure and after 8 months. The angiographic end-points of in-segment and in-stent restenosis of main vessel and/or side branch after 8 months were found in 12.1% versus 6.6% ( P =0.10) and in 10.5% versus 4.5% ( P =0.046) in the crush and culotte groups, respectively. Conclusions— Both the crush and the culotte bifurcation stenting techniques were associated with similar and excellent clinical and angiographic results. Angiographically, there was a trend toward less in-segment restenosis and significantly reduced in-stent restenosis following culotte stenting.